Current Cancer Clinical Trials

Below are the clinical trials we are currently offering at Banner MD Anderson Cancer Center. Please continue to check back as we will continue to add additional trials to this list.

If you are interested in participating in any of these trials, please call (480) 256-6444.

For more information about these trials please visit ClinicalTrials.gov.

Bladder Cancer

A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors (NCT03170960)
Principal Investigator: Dr. Jiaxin Niu

A dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with pembrolizumab and/or chemotherapy for treatment of patients with locally advanced or metastatic urothelial cancer (NCT03288545
Principal Investigator: Santosh Rao

A Phase 3, Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Lenvatinib (E7080/MK-7902) Versus Pembrolizumab and Placebo as First Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma in Cisplatin-ineligible Participants Whose Tumors Express PD-L1, and in Participants Ineligible for Any Platinum-containing Chemotherapy Regardless of PD-L1 Expression (LEAP-011) (NCT03898180
Principal Investigator: Bryan Wong

An Open-label, Phase 1 Study of KHK2455 in Combination With Avelumab in Adult Subjects With Locally Advanced or Metastatic Urothelial Carcinoma (NCT03915405)
Principal Investigator: Santosh Rao

Feasibility Study of Motility Contrast Tomography for Predicting Therapeutic Response Among Bladder Cancer Patients Receiving Neoadjuvant Chemotherapy (NCT03739177)
Principal Investigator: Dr. Joseph Mashni

 

Phase 1/2 Study of TAS-120 in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations (NCT02052778)
Principal Investigator: Dr. Madappa Kundranda

An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors (NCT03767348)
Principal Investigator: Dr. Jiaxin Niu

Kidney Cancer

Prostate Cancer

A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors (NCT03170960)
Principal Investigator: Dr. Jiaxin Niu

A Randomized Phase 3, Open-Label Trial of Sipuleucel-T Administered To Patients On Active Surveillance For Newly Diagnosed Prostate Cancer (NCT03686683)
Principal Investigator: Chinedu Mmeje

Solid Tumor

A Phase 1b/2 Study of FT-2102 in Patients with Advanced Solid Tumors and Gliomas with an IDH1 Mutation (NCT03684811)
Principal Investigator: Dr. Madappa Kundranda

A Phase I/II Study of HB-201 Monotherapy or in Combination with Nivolumab in Patients with Human Papillomavirus 16 Positive (HPV 16+) Confirmed Cancers
Principal Investigator: Dr. Jiaxin Niu

A Phase 2, Non-randomized, Open Label, Single Arm, Multi-center Study Of Talazoparib For Neoadjuvant Treatment Of Germline Brca1/2 Mutation Patients With Early Triple-negative Breast Cancer(NCT03499353)
Principal Investigator: Dr. Lida Mina

A Phase I/II Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Combination With Fulvestrant in Subjects With HR+/HER2- Advanced or Metastatic Breast Cancer (NCT02964507)
Principal Investigator: Dr. Shakeela Bahadur

A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study of DS-8201a, an Anti-HER2-antibody Drug Conjugate, Versus Treatment of Investigator's Choice for HER2-positive, Unresectable and/or Metastatic Breast Cancer Subjects Pretreated With Prior Standard of Care HER2 Therapies, Including T-DM1 (NCT03523585)
Principal Investigator: Dr. Lida Mina

A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors (NCT03170960)
Principal Investigator: Dr. Jiaxin Niu

A Phase II, Open Label, Randomised, Multi-centre Study to Assess the Safety and Efficacy of Agents Targeting DNA Damage Repair in Combination With Olaparib Versus Olaparib Monotherapy in the Treatment of Metastatic Triple Negative Breast Cancer Patients Stratified by Alterations in Homologous Recombinant Repair (HRR)-Related Genes (Including BRCA1/2) (VIOLETTE) (NCT03330847)
Principal Investigator: Dr. Shakeela Bahadur

A Phase 2 Study of ZEN003694 in Combination With Talazoparib in Patients With Triple-Negative Breast Cancer (NCT03901469)
Principal Investigator: Dr. Lida Mina

Phase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination With Pembrolizumab in Advanced Cancer (NCT03674567)
Principal Investigator: Tomislav Dragovich

Effect of Preoperative Breast MRI on Surgical Outcomes, Cost and Quality of Life of Women with Breast Cancer (NCT01805076) 
Principal Investigator: Dr. Julie Billar

A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients With Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NCT01872975)
Principal Investigator: Dr. Emily Grade

Biliary Cancer

A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib Versus Gemcitabine With Cisplatin in Subjects With Advanced/Metastatic or Inoperable Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations: The PROOF Trial (NCT03773302)  
Principal Investigator: Dr. Madappa Kundranda

Phase 1/2 Study of TAS-120 in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations (NCT02052778)
Principal Investigator: Dr. Madappa Kundranda

Colorectal Cancer

A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES) (NCT01349881)
Principal Investigator: Dr. Tomislav Dragovich 

A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer (NCT02921256)
Principal Investigator: Dr.Gary Walker

Phase 1, Two-part (Dose Escalation, Dose Expansion), Multicenter, Non-randomized, Open-label, Multiple Dose, First-in-human Study of CA102N Monotherapy and of CA102N Combined With Trifluridine/Tipiracil (LONSURF) in Subjects With Advanced Solid Tumors (NCT03616574)
Principal Investigator: Dr. Tomislav Dragovich  

A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors (NCT03170960)
Principal Investigator: Jiaxin Niu

Gastric/GEJ

A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors (NCT03170960)
Principal Investigator: Jiaxin Niu

Phase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination With Pembrolizumab in Advanced Cancer (NCT03674567)
Principal Investigator: Dr. Tomislav Dragovich  

Liver Cancer  

REFINE: Regorafenib Observational Study in Hepatocellular Carcinoma (NCT03289273)
Principal Investigator: Dr. Boris Naraev

A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors (NCT03170960)
Principal Investigator: Jiaxin Niu

A Phase 1b/2 Study of FT-2102 in Patients with Advanced Solid Tumors and Gliomas with an IDH1 Mutation (NCT03684811)
Principal Investigator: Madappa Kundranda

A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) versus Placebo as Adjuvant Therapy in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Surgical Resection or Local Ablation (KEYNOTE-937) (NCT03867084)
Principal Investigator: Madappa Kundranda

A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART® Protein binding PD-1 and LAG-3 in Patients with Unresectable or Metastatic Neoplasms (NCT03219268)  
Principal Investigator: Shakeela Bahadur

Neuroendocrine Tumor

Pancreatic Cancer 

A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Following a First-Line Gemcitabine Containing Regimen (NCT02923921)
Principal Investigator: Dr. Tomislav Dragovich

Phase II Study of PEGPH20 and Pembrolizumab (MK-3475) for Patients With Previously Treated Hyaluronan High (HA-High) Metastatic Pancreatic Ductal Adenocarcinoma (NCT03634332)
Principal Investigator: Dr. Tomislav Dragovich

Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma (NCT03377491)
Principal Investigator: Dr. Tomislav Dragovich

A Phase II Study Evaluating Bi-weekly Dosing of Gemcitabine Plus nab-Paclitaxel In The First Line Treatment Metastatic Pancreatic Cancer In Older Adults ( >70 years old)  
Principal Investigator: Madappa Kundranda

Solid Tumor

Phase 1/2 Study of TAS-120 in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations (NCT02052778)
Principal Investigator: Dr. Madappa Kundranda

A Phase 1b/2 Study of FT-2102 in Patients with Advanced Solid Tumors and Gliomas with an IDH1 Mutation (NCT03684811
Principal Investigator: Madappa Kundranda

An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors (NCT03767348
Principal Investigator: Dr. Jiaxin Niu

Cervical Cancer 

A Phase 1 Trial of MK-7684 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors (NCT02964013)
Principal Investigator: Dr. Jiaxan Niu

Phase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination With Pembrolizumab in Advanced Cancer (NCT03674567)
Principal Investigator: Tomislav Dragovich

A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034 (Anti-PD-1) as a Monotherapy or Combination Therapy With AGEN1884 (Anti-CTLA4) or With Placebo in Women With Recurrent Cervical Cancer (Second Line) - RaPiDS (NCT03894215)  
Principal Investigator: Amy Brockmeyer

Ovarian Cancer  

ATHENA (A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy) (NCT03522246)
Principal Investigator: Amy Brockmeyer

A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors (NCT03170960)
Principal Investigator: Dr. Jiaxan Niu

Solid Tumor

A Phase 1b/2 Study of FT-2102 in Patients with Advanced Solid Tumors and Gliomas with an IDH1 Mutation (NCT03684811)
Principal Investigator: Madappa Kundranda

An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors (NCT03767348)
Principal Investigator: Dr. Jiaxan Niu

A Phase I/II Study of HB-201 Monotherapy or in Combination with Nivolumab in Patients with Human Papillomavirus 16 Positive (HPV 16+) Confirmed Cancers
Principal Investigator: Dr. Jiaxan Niu

An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors (NCT03767348)
Principal Investigator: Dr. Jiaxin Niu

A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors (NCT03170960
Principal Investigator: Dr. Jiaxin Niu

A Phase I/II Study of HB-201 Monotherapy or in Combination with Nivolumab in Patients with Human Papillomavirus 16 Positive (HPV 16+) Confirmed Cancers
Principal Investigator: Dr. Jiaxin Niu

A Phase I/II Study of NBTXR3 Activated by SABR for Patients With Advanced HNSCC or NSCLC Treated With an Anti-PD1 Antibody (NCT03589339
Principal Investigator: Dr. Jiaxin Niu

Phase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination With Pembrolizumab in Advanced Cancer (NCT03674567)
Principal Investigator: Tomislav Dragovich

A Phase 1/2 Study of Combination Immunotherapy and mRNA Vaccine in Subjects with Nonsmall Cell Lung Cancer (NSCLC) (NCT03164772)
Principal Investigator: Dr. Jiaxin Niu

A Multicenter, Two-Part, Phase 2 Clinical Study of CMP-001 in Combination with atezolizumab with and without radiation therapy in Subjects with Advanced Non-Small Cell Lung Cancer (NSCLC) (NCT03438318)
Principal Investigator: Dr. Jiaxin Niu

A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy +/-Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants with Resectable Stage IIB or IIIA Non-small Cell Lung Cancer (NSCLC) (KEYNOTE-671) (NCT03425643)
Principal Investigator: Dr. Qing Zhao

A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors (NCT03170960)
Principal Investigator: Dr. Jiaxin Niu

A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral EGFR/HER2 Inhibitor TAK-788 (AP32788) in Non-Small Cell Lung Cancer (NCT02716116)
Principal Investigator: Dr. Jiaxin Niu

A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART® Protein binding PD-1 and LAG-3 in Patients with Unresectable or Metastatic Neoplasms (NCT03219268)
Principal Investigator: Shakeela Bahadur

Phase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination With Pembrolizumab in Advanced Cancer (NCT03674567)
Principal Investigator: Tomislav Dragovich

An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors (NCT03767348)
Principal Investigator: Dr. Jiaxin Niu

A Phase 1b/2 Study of FT-2102 in Patients with Advanced Solid Tumors and Gliomas with an IDH1 Mutation (NCT03684811)
Principal Investigator: Madappa Kundranda

An Observational Registry Study to Evaluate the Performance of the BDX-XL2 Test (NCT03766958)
Principal Investigator: Dr. Archan Shah

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B Cell or T Cell Non-Hodgkin Lymphoma (NHL) (NCT01994382)
Principal Investigator: Dr. Javier Munoz 

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel versus Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7) (NCT03391466) 
Principal Investigator: Dr. Javier Munoz

A Phase 2 Study of Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy in Adult Patients With Aggressive B-cell NHL (017006) (NCT03483103)
Principal Investigator: Dr. Javier Munoz (Please note: The study recruitment for this study are currently on hold)

A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (iNHL) (NCT03105336)
Principal Investigator: Dr. Javier Munoz

A Phase Ib/II, Open-Label, Multicenter, Randomized, Controlled Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Patients With B-Cell Non-Hodgkin Lymphoma (NCT03677141)
Principal Investigator: Dr. Javier Munoz

An Open-Label, Phase 1 Safety and Phase 2 Randomized Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)(NCT03331198)
Principal Investigator: Dr. Javier Munoz 

A Phase 2 Multicenter Study Evaluating the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Subjects With High-Risk Large B-Cell Lymphoma (ZUMA-12) (NCT03761056)
Principal Investigator: Dr. Javier Munoz

A Phase 1/Phase 2 Clinical Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants with Hematologic Malignancies (NCT03598608)
Principal Investigator: Dr. Javier Munoz

Phase 1, Multicenter, Open-Label Study of the Antibody-Drug Conjugate TRPH-222 in Subjects With Relapsed and/or Refractory B-Cell Lymphoma (NCT03682796)  
Principal Investigator: Dr. Javier Munoz

A Phase 1/Phase 2 Clinical Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants with Hematologic Malignancies (NCT03598608)
Principal Investigator: Dr. Javier Munoz

A Phase 2 Study of Daratumumab Subcutaneous (Dara-SC) Administration in Combination With Carfilzomib and Dexamethasone (DKd) Compared With Carfilzomib and Dexamethasone (Kd) in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab Intravenous (Dara-IV) to Evaluate Daratumumab Retreatment (NCT03871829)
Principal Investigator: Sumit Madan

A Single-Arm, Open-Label, Phase 1 Study of the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-715 to Evaluate an Anti-BCMA Allogeneic CAR T Cell Therapy in Subjects With Relapsed/Refractory Multiple Myeloma (NCT04093596
Principal Investigator: Rajneesh Nath

Breast Cancer

A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients With Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NCT1872975)
Principal Investigator: Dr.Emily Grade

Bone Metastases

A randomized trial evaluating rapid delivery of dose escalated hypofractionated radiotherapy for patients diagnosed with bone metastases for effective palliation of
symptoms
 (NCT02163226)
Principal Investigator: Dr.Gary Walker 

Head and Neck Cancer

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Superoxide Dismutase Mimetic GC4419 to Reduce Severe Oral Mucositis (SOM) Associated with Chemoradiotherapy for Locally Advanced, Non-Metastatic Head and Neck Cancer (NCT03689712)
Principal Investigator: Dr.Gary Walker

Prostate Cancer

Prospective Data Registry and Quality of Life Assessment of Men Undergoing High Dose Rate Brachytherapy of the Prostate Using Real-Time Ultrasound Planning 
Principal Investigator: Dr. Anna Likhacheva

Prospective Evaluation of Men Undergoing Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer
Principal Investigator: Dr. Rachit Kumar

Rectal Cancer

A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer (NCT02921256)
Principal Investigator: Dr.Gary Walker

Skin Cancer

Skin Surface Brachytherapy for Non-Melanoma Skin Cancers: Prospective Data Registry and Quality of Life Assessment
Principal Investigator: Dr.Emily Grade

Solid Tumor

EXTernal beam radiation to Eliminate Nominal metastatic Disease (EXTEND): A randomized phase II basket trial assessing the efficacy of upfront local consolidative therapy (LCT) for oligometastatic disease (NCT03599765)
Principal Investigator: Dr.Gary Walker